Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis
Journal article
McClung, Michael R., Zanchetta, Jose Ruben, Høiseth, Arne, Kendler, David L., Yuen, Chui Kin, Brown, Jacques P., Stonkus, Sigtas, Goemaere, Stefan, Recknor, Christopher, Woodson, Grattan C., Bolognese, Michael A., Franek, Edward, Brandi, Maria Luisa, Wang, Andrea and Libanati, Cesar. (2013). Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. Journal of Clinical Densitometry. 16(2), pp. 250 - 256. https://doi.org/10.1016/j.jocd.2012.02.014
Authors | McClung, Michael R., Zanchetta, Jose Ruben, Høiseth, Arne, Kendler, David L., Yuen, Chui Kin, Brown, Jacques P., Stonkus, Sigtas, Goemaere, Stefan, Recknor, Christopher, Woodson, Grattan C., Bolognese, Michael A., Franek, Edward, Brandi, Maria Luisa, Wang, Andrea and Libanati, Cesar |
---|---|
Abstract | FREEDOM was a phase 3 trial in 7808 women aged 60–90 yr with postmenopausal osteoporosis. Subjects received placebo or 60 mg denosumab subcutaneously every 6 mo for 3 yr in addition to daily calcium and vitamin D. Denosumab significantly decreased bone turnover; increased dual-energy X-ray absorptiometry (DXA) areal bone mineral density (aBMD); and significantly reduced new vertebral, nonvertebral, and hip fractures. In a subset of women (N = 209), lumbar spine, total hip, and femoral neck volumetric BMD (vBMD) were assessed by quantitative computed tomography at baseline and months 12, 24, and 36. Significant improvement from placebo and baseline was observed in aBMD and vBMD in the denosumab-treated subjects at all sites and time points measured. The vBMD difference from placebo reached 21.8%, 7.8%, and 5.9%, respectively, for the lumbar spine, total hip, and femoral neck at 36 mo (all p ≤ 0.0001). Compared with placebo and baseline, significant increases were also observed in bone mineral content (BMC) at the total hip (p < 0.0001) largely related to significant BMC improvement in the cortical compartment (p < 0.0001). These results supplement the data from DXA on the positive effect of denosumab on BMD in both the cortical and trabecular compartments. |
Keywords | bone density; denosumab; osteoporosis; quantitative computed tomography |
Year | 2013 |
Journal | Journal of Clinical Densitometry |
Journal citation | 16 (2), pp. 250 - 256 |
Publisher | Humana Press, Inc. |
ISSN | 1094-6950 |
Digital Object Identifier (DOI) | https://doi.org/10.1016/j.jocd.2012.02.014 |
Page range | 250 - 256 |
Research Group | Institute for Health and Ageing |
Publisher's version | File Access Level Controlled |
Place of publication | United States of America |
https://acuresearchbank.acu.edu.au/item/8669q/denosumab-densitometric-changes-assessed-by-quantitative-computed-tomography-at-the-spine-and-hip-in-postmenopausal-women-with-osteoporosis
Restricted files
Publisher's version
96
total views0
total downloads2
views this month0
downloads this month